We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases

Our lead drug candidate is lirentelimab (AK002), an investigational antibody that targets Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. In clinical and preclinical studies, lirentelimab has been shown to broadly inhibit mast cells and rapidly deplete eosinophils.

Our most advanced clinical programs are in eosinophilic gastrointestinal diseases (EGIDs), inflammatory diseases characterized by persistent gastrointestinal symptoms with elevated eosinophils and mast cells in the esophagus, stomach, duodenum and/or colon. Lirentelimab has demonstrated positive clinical activity in several mast cell and eosinophil driven diseases, including in a Phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis  (EoD, previously referred to as EGE in this study). Other indications where lirentelimab has shown clinical activity are chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.